HIA
SUPN icon

HFM Investment Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

HFM Investment Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140 Buy
3
+1
+50% +$48 ﹤0.01% 1214
2026
Q1 		$103 Hold
2
– – ﹤0.01% 1116
2025
Q4 		$100 Hold
2
– – ﹤0.01% 1173
2025
Q3 		$96 Buy
2
+1
+100% +$40 ﹤0.01% 1162
2025
Q2 		$32 Buy
+1
New +$32 ﹤0.01% 1249

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

HFM Investment Advisors's SUPN Position: Q2 2026 in Review

HFM Investment Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 50% in Q2 2026, buying an estimated $48 and bringing the position to 3 shares worth $140. The position accounts for ﹤0.01% of the portfolio, ranked #1214.

HFM Investment Advisors first reported a position in SUPN in Q2 2025 and has held it in 5 quarters since. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • HFM Investment Advisors held 3 shares of Supernus Pharmaceuticals worth $140 as of Q2 2026.
  • HFM Investment Advisors bought 1 Supernus Pharmaceuticals share in Q2 2026, an estimated $48.
  • Supernus Pharmaceuticals made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #1214 holding.
  • HFM Investment Advisors first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.